Inical Research Of Tace With3-dcrt To Treat Primary Hepatic Carcinoma With Portal Vein Tumor Thrombus

purpose To evaluate the clinical efficacy of the transcatheter arterial chemoembolization combined with three-dimentional conformal radiotherapy to treat Primary liver cancer with portal vein tumor thrombus.Methods we retrospectively study and analyze the94Primary liver cancer with portal vein tumor thrombus cases of Guangxi Medical University Cancer Hospital.41cases of them are treated group using the treatment of the TACE combined with3DCRT,and the rest of53cases are control group only using the treatment of the TACE. We observed the recent efficacy of the two groups, including tumor remission rate, the remission rate of PVTT, the decrease rate (more than50%)of serum AFP levels, the average survival time(Use Kaplan-Meier survival analysis) and side effect.Results The reexamination and evaluation of hepatic tumor is performed in3months after the end treatment.1. The tumor remission rate in the treated group and the control group was70.7%and47.1%,and there were statistically differences between them(p<0.05).2. The remission rate of PVTT in the treated group and the control group was65.8%and28.3%, and there were also significant differences in the statistics between the two groups(p<0.05).3. The decrease rate (more than50%)of serum AFP levels in the treated group and the control group was70.7%and47.1%,and the difference was statistically significant(p<0.05).4. The average survival rates of the treated group were(78.0)%,(51.2)%and(4.9)%at6months,1,2years, respectively, with a median survival time of13months and an average survival time of12.6months; the average survival rates of the control group were(67.9)%,(13.2)%and(0.0)%at6months,1,2years, respectively, with a median survival time of7.5months and an average survival time of8.6months; there were statistical significance between the treated group and the control group(p<0.05).5. side effect:no statistical significance was obtained in the side effect between the two groups.Conclusions the transcatheter hepatic arterial chemoembolization combined with three-dimentional conformal radiotherapy for primary liver cancer with portal vein tumor thrombus can improve efficacy and prolong survival, but does not increase side effects.